Plexium, a San Diego, CA-based targeted protein degradation (TPD) company, raised $102M in funding. The round was led by BVF Partners, L.P. and TCG X, with participation from Softbank Vision Fund 2, RA Capital Management, Surveyor Capital, Pappas Capital, The Column Group, DCVC Bio, Pivotal bioVenture Partners, Lux Capital, M Ventures, CRV and Neotribe Ventures. [...]The post Plexium Raises $102M Financing appeared first on FinSMEs.
Plexium is a California-based biotechnology company that develops a platform that provides targeted protein degradation therapies for the treatment of cancer.